A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SARS-CoV-2 Neutralizing Antibody BGB-DXP593 in Patients With Mild-to-Moderate COVID

  • McMahon, James (Primary Chief Investigator (PCI))
  • Roney, Janine J. (Project Manager)

Project: Research

Project Details

StatusFinished
Effective start/end date26/10/208/01/21

Keywords

  • SARS CoV2
  • COVID-19
  • Clinical trial